AbbVie Reports Positive Phase 3 Trial Results for Etentamig

The CERVINO trial, which involved 393 patients, demonstrated that etentamig achieved an objective response rate of 74%, significantly outperforming the 45.7% seen in patients receiving standard therapies. The trial also recorded a 60% reduction in the risk of disease progression or death, according to findings presented by the company. Following these results, the Independent Data Monitoring Committee recommended unblinding the study ahead of schedule.

Clinicians highlighted the treatment's safety profile, noting that a single step-up dose followed by monthly administration led to low rates of cytokine release syndrome and other severe adverse events. Researchers suggest this dosing schedule could expand treatment accessibility, potentially allowing for the administration of the therapy in outpatient and community-based settings rather than exclusively in specialized hospitals. AbbVie intends to present the full data set at the 23rd International Myeloma Society Annual Meeting in Glasgow this September and initiate discussions with global regulatory authorities regarding the next steps for approval.